JeanMarie Guenot is currently the CEO and President of Amphivena Therapeutics, Inc. The Company has been in operation since July 2013 and has its base in San Francisco, California. It is a preclinical stage company with a mission to eradicate blood cancers using breakthrough therapies that draw strength from the human immune system in a bid to destroy tumor cells and everything that aids their growth. The goal is to restore cellular balance necessary for sufficient blood formation, proper blood function and free-following blood circulation on guenotllc.com. In other word, the company is overwhelmed with giving hope to patients suffering from life threatening illnesses by restoring the flow of life.
Dr. Jeanmarie Guenot is not a new face in the pharmaceutical and biotechnology industry having been in it for over 20 years. She has experience in virtually all stages of companies, whether public or private, whether pharmaceutical R&D or corporate & commercial development, and whether business development, project & alliance management or venture capital. Aside interest, she also has expertise in setting up companies and rebuilding those ones in comatose.
Before taking up her current role in Amphivena Therapeutics, Inc. Dr. JeanMarie Guenot was in charge of SKS Ocular, a company she founded and built. SKS is a start-up ophthalmic company that focuses on sustained release ocular drug delivery technologies, dry AMD and therapeutics for macular degeneration, ocular inflammation and glaucoma. The likes of Hoffmann-La Roche in Basel and Shanghai engaged her as a business adviser. She led mergers, licensing, commercial product portfolios, acquisitions and alliance management for PDL’s R&D while she was vice president in charge of Corporate & Business Development at PDL BioPharma.
JeanMarie Guenot holds a PhD from the University of California, San Francisco and a MBA from The Wharton School at the University of Pennsylvania. She has extensive experience in the areas of autoimmune diseases, cardiovascular diseases, neurology, ophthalmic diseases and oncology.
Learn more about Jeanmarie Guenot: http://www.businesswire.com/news/home/20170111005414/en/Maverick-Therapeutics-Takeda-Announce-Five-year-Collaboration-Advance